Alogliptin Benzoate Intermediates: CDMO Sourcing Guide 2026
Alogliptin Benzoate Intermediates: CDMO Sourcing Guide 2026
For formulators and API manufacturers working in the DPP-4 inhibitor space, Alogliptin Benzoate (CAS 850649626) sits at an awkward point in the supply chain. Demand is steady, the chemistry is well characterized, and yet procurement teams repeatedly report the same problems: inconsistent batch quality, fragmented supplier rosters, and long lead times on the very intermediates that determine whether a project can be scaled at all. This guide examines what Alogliptin Benzoate is, why sourcing it reliably is harder than it looks, and how the capability system behind Tianming Pharmaceutical Group is structured to close those gaps.
What Is Alogliptin Benzoate?
Alogliptin Benzoate is the benzoate salt form of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes. In the pharmaceutical supply chain it appears in two distinct roles: as a finished API supplied to formulation companies, and as a member of a broader family of anti-diabetic intermediates whose individual building blocks must be sourced, qualified, and documented in parallel.
That second role is where supply risk concentrates. An Alogliptin Benzoate program does not depend on a single compound. It depends on a set of upstream building blocks that must arrive with matching specifications, compatible process parameters, and traceable documentation.
The Upstream Building Blocks Behind Alogliptin Benzoate
Tianming Pharmaceutical Group supplies a coordinated set of intermediates along this route, including:
- 2-Cyanobenzyl Bromide (CAS 22115419) — a benzonitrile-derived alkylating building block
- 6-Chloro-3-methyluracil (CAS 4318563) — a chlorinated uracil heterocycle used in the pyrimidinedione core
- 2-[[3-(3-Amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile (CAS 865758969) — an advanced piperidinyl-substituted intermediate positioned late in the route
- Alogliptin Benzoate (CAS 850649626) — the finished salt-form API
Sourcing these four nodes from four different vendors is a common industry practice, and it is also a common source of delay. Each supplier carries its own batch history, its own analytical methods, and its own tolerance for specification drift. When those tolerances diverge, the mismatch typically surfaces during scale-up rather than during R&D — the most expensive possible moment to discover it. Tianming Pharmaceutical Group addresses this by offering the full ladder from a single coordinated supply base, which removes multi-supplier coordination overhead from the customer's side.
Why Alogliptin Benzoate Supply Is Difficult to Secure
The pain points reported across the anti-diabetic intermediate market are consistent and well documented:
- Extended lead times for high-end specialty intermediates, particularly as programs move from pilot to commercial scale
- Volatile raw material pricing that destabilizes procurement budgeting across a fiscal year
- Inconsistent batch quality that causes production interruptions and rework
- Fragmented sourcing across multiple suppliers, which raises total procurement cost even when unit prices look competitive
- Difficulty matching process parameters for niche intermediate categories
- Upstream product introductions that lag behind new drug iteration cycles
Within the anti-diabetic products category, these pressures are amplified because DPP-4 inhibitors, SGLT2 inhibitors, and oral GLP-1 receptor agonist intermediates compete for the same reactor capacity. A supplier that cannot sequence production across therapeutic families will produce unpredictable lead times regardless of how strong its individual chemistry is.
How Tianming Pharmaceutical Group Is Positioned
Tianming Pharmaceutical Group is a National High-Tech Enterprise operating an integrated R&D-production model, founded in 2020 and building on predecessor Shandong Sihuan Pharmaceutical Co., Ltd., established in 2010. The group provides API, intermediates, and CMO/CDMO custom development and production solutions to the global pharmaceutical industry, with business coverage across 30+ countries and regions including South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.
Its anti-diabetic portfolio contains 36 products spanning DPP-4 inhibitors, SGLT2 inhibitors, and oral GLP-1 intermediates — meaning Alogliptin Benzoate is supplied within a matrix rather than as an isolated offering. Adjacent products in the same line include Alogliptin Benzoate, Linagliptin, Dapagliflozin Monohydrate Propylene Glycol, Empagliflozin, Tetraacetyl Dapagliflozin, and Tetraacetyl Empagliflozin.
The Three-Base Capacity Model
Capacity is the constraint that most often breaks an intermediate supply relationship. Tianming Pharmaceutical Group coordinates three production bases — Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Shandong; Jining Tianming Pharmaceutical Co., Ltd. in Jining, Shandong; and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi, Guangxi — with over 160 reactor vessels and annual production capacity in the hundreds of tons. Two R&D centers, in Jinan and Nanjing, operate over 6,000 square meters of laboratory space with 100+ R&D personnel and RMB 40+ million in analytical instrumentation including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis equipment.
For an Alogliptin Benzoate program, this structure supports gram-level through ton-level supply without a change of supplier as the project advances. Orders are placed against CRM, ERP, and BPM digital management systems that handle order management, inventory, production scheduling, and customer service coordination.
Quality Specifications and Documentation
Quality performance in this category is measured against explicit attributes. Related product lines from the same group operate under specifications such as individual impurity below 0.1%, total impurities below 0.5%, enantiomer below 0.1%, and content above 98.0% on high-purity intermediates, with strict monitoring of chiral impurities, residual solvents, particle size, and crystal form.
Documentation is delivered as a complete package: COA, MOA methodology, impurity profile studies, and stability data, supporting customer DMF and CEP global regulatory filings. Batch traceability extends across raw material receipt, reaction parameters, purification processes, and testing data, with all records archived for full chain-of-custody traceability. ISO9001 Quality Management System Certification is held by Shandong Sihuan Pharmaceutical Co., Ltd. (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. (2024).
Delivery and Technical Support
In-stock orders are delivered within 7–15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability, with expedited production scheduling available for urgent projects. International orders are supported through logistics coordination plus customs clearance and trade insurance assistance, with cold chain available for temperature-sensitive products.
Support runs on a 1-on-1 account manager plus technical engineer dual model: routine technical issues receive reference solutions within 2 hours, and complex issues receive a written report within 24 hours.
Who This Supply Model Serves
Tianming Pharmaceutical Group serves 2,000+ cooperative customers, concentrated in East China, North China, and South China pharmaceutical clusters domestically, and across South Asia, the Middle East, and Southeast Asia internationally. In the anti-diabetic segment, buyers span listed pharmaceutical companies, SME pharmaceutical companies, CRO/CDMO institutions, and specialized biochemical companies.
Key Takeaways
- Alogliptin Benzoate sourcing decisions are really decisions about the entire upstream route, not one compound.
- Consolidating 2-Cyanobenzyl Bromide, 6-Chloro-3-methyluracil, CAS 865758969, and Alogliptin Benzoate under one supplier removes coordination cost and specification drift.
- Three production bases and 160+ reactor vessels provide the capacity elasticity that DPP-4, SGLT2, and GLP-1 programs collectively demand.
- Registration-grade documentation — COA, MOA methodology, impurity profiles, and stability data — supports DMF and CEP filings directly.
- The dual account manager and technical engineer model compresses technical response to 2 hours and written resolution to 24 hours.
For organizations building or defending an anti-diabetic portfolio, the practical question is not whether Alogliptin Benzoate can be sourced, but whether it can be sourced reproducibly, at scale, with documentation that survives regulatory scrutiny. Tianming Pharmaceutical Group is structured around that specific requirement.
Tianming Pharmaceutical Group
